Expresión del Her2/neu en pacientes diagnosticadas de cáncer de mama, ION SOLCA Dr. Juan Tanca Marengo 2006-2010
Fecha
2012
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Médicas. Escuela de Graduados
Resumen
El carcinoma de mama continúa siendo una de las principales causas de muerte por cáncer entre las mujeres en todo el mundo. Su incidencia crece cada año un 1%. La epidemia del cáncer de mama constituye una prioridad en salud pública. La evidencia reciente demuestra que el carcinoma de mama es hoy en día una de las principales causas de muerte y discapacidad en Ecuador. En forma paralela, la investigación ha producido nuevas opciones terapéuticas, muchas de las cuales tienen un costo elevado. Por consiguiente, la epidemia de carcinoma de mama representa un nuevo desafío para el financiamiento de su tratamiento por parte del Estado. El oncogén HER2 que se encuentra sobre-expresado en casi un tercio de las pacientes, se constituye en una importante diana terapéutica. Conocer el pronóstico de un paciente con cáncer permite elegir una terapéutica más apropiada. El HER2neu es una oncoproteína que se expresa en las células de los carcinomas de mama, y confiere un comportamiento agresivo y de metástasis. Este fenómeno se ha utilizado como parámetro pronóstico y como factor predictivo y de indicación para tratamiento con anticuerpos monoclonales dirigidos contra esta proteína. En este sentido se realizó un estudio tipo observacional, descriptivo, con un diseño no experimental, longitudinal y retrospectivo que recopiló información de 100 pacientes atendidos del 2006 al 2010 en el Instituto Oncológico Nacional de la Sociedad de Lucha Contra el Cáncer “Dr. Juan Tanca Marengo”, observándose que la positividad del HER2/neu es del 29 % y de los receptores hormonales del 48%. La verificación del status del HER2/neu se realizó mediante inmunohistoquímica, utilizando la técnica de avidina-estreptavidina-peroxidasa. Para la interpretación del HER2/neu se asignó una puntuación de 0 a 3+ acorde con las pautas de interpretación del Hercep-Test (DAKO). Este trabajo da a conocer el porcentaje de positividad del HER2/neu y su relación con los receptores hormonales en las pacientes ecuatorianas con carcinoma ductal de mama.
Breast carcinoma remains a leading cause of cancer death among women worldwide. Its incidence increases each year by 1%. The breast cancer epidemic is a public health priority. Recent evidence shows that breast cancer is now one of the main causes of death ¬ and disability in Ecuador. In parallel, research has produced new cas ¬ therapeutic options, many of which are expensive. Therefore, the breast cancer epidemic represents a new challenge for the financing of its treatment by the state. The oncogene HER2 is overexpressed in nearly one third of patients, constitutes an important therapeutic target. Knowing the prognosis of a cancer patient can choose a more appropriate treatment. The HER2neu oncoprotein is expressed in cells of breast carcinomas, and confers aggressive behavior and metastasis. This phenomenon has been used as prognostic parameter and as a predictor and indication for treatment with monoclonal antibodies directed against this protein. In this sense, a study was conducted observational, descriptive, longitudinal and retrospective study design that collected data from 100 patients treated from 2006 to 2010 at the National Cancer Institute of the Society for Fight Against Cancer "Dr. Juan Tanca Marengo ", noting that HER2/neu positivity is 29% and 48% hormone receptor. Verification of HER2/neu status by immunohistochemistry was performed using the technique of avidin-streptavidinperoxidase. For the interpretation of HER2/neu was assigned a score from 0 to 3 + according to the guidelines for the interpretation of Hercep-Test (DAKO). This paper discloses the percentage of positive HER2/neu and its relationship to hormone receptors in patients with ductal carcinoma Ecuadorian breast....
Breast carcinoma remains a leading cause of cancer death among women worldwide. Its incidence increases each year by 1%. The breast cancer epidemic is a public health priority. Recent evidence shows that breast cancer is now one of the main causes of death ¬ and disability in Ecuador. In parallel, research has produced new cas ¬ therapeutic options, many of which are expensive. Therefore, the breast cancer epidemic represents a new challenge for the financing of its treatment by the state. The oncogene HER2 is overexpressed in nearly one third of patients, constitutes an important therapeutic target. Knowing the prognosis of a cancer patient can choose a more appropriate treatment. The HER2neu oncoprotein is expressed in cells of breast carcinomas, and confers aggressive behavior and metastasis. This phenomenon has been used as prognostic parameter and as a predictor and indication for treatment with monoclonal antibodies directed against this protein. In this sense, a study was conducted observational, descriptive, longitudinal and retrospective study design that collected data from 100 patients treated from 2006 to 2010 at the National Cancer Institute of the Society for Fight Against Cancer "Dr. Juan Tanca Marengo ", noting that HER2/neu positivity is 29% and 48% hormone receptor. Verification of HER2/neu status by immunohistochemistry was performed using the technique of avidin-streptavidinperoxidase. For the interpretation of HER2/neu was assigned a score from 0 to 3 + according to the guidelines for the interpretation of Hercep-Test (DAKO). This paper discloses the percentage of positive HER2/neu and its relationship to hormone receptors in patients with ductal carcinoma Ecuadorian breast....
Descripción
PDF
Palabras clave
Neoplasias de la mama, Oncogén Her2/Neu, Epidemiología descriptiva, Estudios retrospectivos, Hospital SOLCA de Guayaquil, Cantón Guayaquil, Ecuador